Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT ID: NCT01335191

Last Updated: 2013-02-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-06-30
• Study Completion Date: 2012-06-30

Brief Summary

This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.

Detailed Description

In this study, HIV-1 infected subjects on ART, with undetectable HIV-1 viral load, will be immunized with 1mg TUTI-16 or placebo in a randomized double blind fashion (prime and 3 week boost). Three weeks after the 3 week boost (week 6) ART will be stopped. HIV-1 viral load and CD4+ T-cell levels will be determined at defined intervals through 54 weeks (48 weeks Post ART discontinuation).

Conditions

HIV Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

TUTI-16 (1.0 mg)

Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.

Group Type: EXPERIMENTAL

TUTI-16 (1.0 mg)

Intervention Type: BIOLOGICAL

Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.

Placebo

Two subcutaneous injections of placebo at Day 0 and Week 3.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Two subcutaneous injections of Placebo at Day 0 and Week 3.

Interventions

TUTI-16 (1.0 mg)

Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.

Intervention Type: BIOLOGICAL

Placebo

Two subcutaneous injections of Placebo at Day 0 and Week 3.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Males and Females
• Age ≥ 18 and ≤ 50 years at Screening
• Body weight of 50-100 kg (inclusive) at Screening.
• HIV-1 seropositive subjects on effective ART for > 12 months (undetectable HIV plasma viremia), viral set point before ART > 10,000.
• CD4+ T-cell count ≥ 500/mm3.
• No antiviral drug within 8 weeks of screening. Patients stabilized on Aciclovir and Valciclovir for more than 6 months may be enrolled.
• Karnofsky performance status > 90% at screening.
• In good health as determined by medical history, a baseline physical examination, vital signs, and clinical laboratory tests.
• Subject is willing and able to sign written informed consent prior to beginning study procedures.
• Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.

Exclusion Criteria

• Females planning to become pregnant during the course of the study.
• Females with a positive pregnancy test at Screening or study enrollment.
• Any out-of range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Principal Investigator.
• Systemic infection or other vaccination within 6 weeks prior to screening. Live vaccine within 1 year of screening.
• Autoimmune disease (e.g., psoriasis, rheumatoid arthritis, etc.) or inflammatory bowel disease confirmed by clinical history.
• Positive at screen for HBV (by HBsAg assay) or HCV (by antibody ELISA) unless there is no active infection as judged by an elevated alanine aminotransferase (ALT) at screening.
• Alanine aminotransferase (ALT) above the upper limit of normal at screening.
• Hemoglobin outside of laboratory normal range at screening.
• Absolute neutrophil counts outside of laboratory normal range at screening.
• Platelet count outside of laboratory normal range at screening.
• A history of significant drug allergy.
• A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the informed consent.
• Subjects experiencing an acute Herpetic event.
• Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Principal Investigator would make the subject unsuitable for the study or put them at additional risk.
• Routine or PRN consumption of immune suppressive medications that the subject is unable or unwilling to discontinue during the study.
• Inability to understand or follow study instructions.
• Participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Thymon, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mardik Donikyan, MD

Role: PRINCIPAL_INVESTIGATOR

Clinilabs, Inc.

Locations

Clinilabs

New York, New York, United States

Countries

United States

References

Goldstein G, Damiano E, Donikyan M, Pasha M, Beckwith E, Chicca J. HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia. Hum Vaccin Immunother. 2012 Oct;8(10):1425-30. doi: 10.4161/hv.21616. Epub 2012 Oct 1.

Reference Type: DERIVED

PMID: 23095869 (View on PubMed)

Other Identifiers

THYMON-11001

Identifier Type: -

Identifier Source: org_study_id